LTPA2017035I1 - Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu - Google Patents

Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Info

Publication number: LTPA2017035I1
Authority: LT; Lithuania
Prior art keywords: morphine; antibody; treatment; combination
Prior art date: 2009-08-14

Application number

LTPA2017035C

Other languages

English (en)

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-14

Filing date

2017-10-31

Publication date

2017-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2017035(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-10-31 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2017-11-27 Publication of LTPA2017035I1 publication Critical patent/LTPA2017035I1/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTPA2017035C 2009-08-14 2017-10-31 Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu LTPA2017035I1 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09010489		2009-08-14
PCT/EP2010/004939 WO2011018224A1 (en)	2009-08-14	2010-08-12	Combination therapy of an afucosylated cd20 antibody with bendamustine
EP10747168.2A EP2464382B1 (en)	2009-08-14	2010-08-12	Combination therapy of an afucosylated cd20 antibody with bendamustine

Publications (1)

Publication Number	Publication Date
LTPA2017035I1 true LTPA2017035I1 (lt)	2017-11-27

Family

ID=41351729

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP10747168.2T LT2464382T (lt)	2009-08-14	2010-08-12	Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu
LTPA2017035C LTPA2017035I1 (lt)	2009-08-14	2017-10-31	Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP10747168.2T LT2464382T (lt)	2009-08-14	2010-08-12	Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu

Country Status (34)

Country	Link
US (4)	US20110165151A1 (lt)
EP (1)	EP2464382B1 (lt)
JP (3)	JP5646626B2 (lt)
KR (1)	KR101425736B1 (lt)
CN (2)	CN107261138A (lt)
AR (1)	AR077866A1 (lt)
AU (1)	AU2010281866B2 (lt)
CA (1)	CA2769674C (lt)
CL (1)	CL2012000391A1 (lt)
CR (1)	CR20120036A (lt)
CY (2)	CY1119251T1 (lt)
DK (1)	DK2464382T3 (lt)
ES (1)	ES2630158T3 (lt)
HK (1)	HK1245145A1 (lt)
HR (1)	HRP20170972T1 (lt)
HU (2)	HUE033531T2 (lt)
IL (1)	IL217753A (lt)
LT (2)	LT2464382T (lt)
LU (1)	LUC00045I2 (lt)
MA (1)	MA33469B1 (lt)
MX (2)	MX355849B (lt)
MY (1)	MY163003A (lt)
NO (1)	NO2017054I1 (lt)
NZ (1)	NZ597666A (lt)
PL (1)	PL2464382T3 (lt)
PT (1)	PT2464382T (lt)
RS (1)	RS56146B1 (lt)
SG (1)	SG178324A1 (lt)
SI (1)	SI2464382T1 (lt)
SM (1)	SMT201700329T1 (lt)
TW (1)	TWI409079B (lt)
UA (1)	UA110096C2 (lt)
WO (1)	WO2011018224A1 (lt)
ZA (1)	ZA201200830B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004026470D1 (de)	2003-11-05	2010-05-20	Roche Glycart Ag	Fc-rezeptor und effektorfunktion
EP2641618A3 (en)	2007-07-16	2013-10-23	Genentech, Inc.	Humanized anti-CD79B antibodies and immunoconjugates and methods of use
RS52305B (en)	2007-07-16	2012-12-31	Genentech Inc.	ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
EP2247620B1 (en)	2008-01-31	2016-05-18	Genentech, Inc.	Anti-cd79b antibodies and immunoconjugates and methods of use
LT2578585T (lt)	2010-05-31	2016-10-10	Ono Pharmaceutical Co., Ltd.	Purinono darinys kaip btk kinazės inhibitorius
FR2976811A1 (fr) *	2011-06-22	2012-12-28	Lfb Biotechnologies	Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
MX354479B (es) *	2011-08-16	2018-03-07	Morphosys Ag	Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
HUE058855T2 (hu) *	2011-08-16	2022-09-28	Morphosys Ag	Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
FR2980110A1 (fr) *	2011-09-20	2013-03-22	Lfb Biotechnologies	Combinaison d'anticorps anti-cd20 et de bendamustine
EP2786996B1 (en)	2011-11-29	2016-09-14	ONO Pharmaceutical Co., Ltd.	Purinone derivative hydrochloride
CN103375132A (zh) *	2012-04-24	2013-10-30	长江大学	井下旋转冲击式钻井工具
EP2762496A1 (en)	2013-02-05	2014-08-06	EngMab AG	Method for the selection of antibodies against BCMA
CN104968682A (zh)	2013-02-05	2015-10-07	英格玛布股份公司	针对CD3ε和BCMA的双特异性抗体
US20160101199A1 (en)	2013-06-07	2016-04-14	Nordic Nanovector As	Method for upregulating antigen expression
EP3122360B1 (en)	2014-03-25	2020-06-17	ONO Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
PT3262071T (pt)	2014-09-23	2020-06-16	H Hoffnabb La Roche Ag	Métodos de utilização de imunoconjugados anti-cd79b
US10239879B2 (en)	2015-04-09	2019-03-26	Ono Pharmaceutical Co., Ltd.	Process for producing purinone derivative
SMT202000139T1 (it)	2015-08-03	2020-05-08	Engmab Sarl	Anticorpi monoclonali contro l'antigene umano di maturazione delle cellule b (bcma)
EP3257866A1 (en) *	2016-06-17	2017-12-20	Academisch Medisch Centrum	Modified anti-tnf antibody and use thereof in the treatment of ibd
BR112019008426A2 (pt)	2016-11-02	2019-09-03	Engmab Sarl	anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
CA3046489A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en)	2017-03-30	2022-12-28	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
IL278853B2 (en)	2018-05-23	2025-06-01	Celgene Corp	Antiproliferative compounds and a bispecific antibody against BCMA and CD3 for combined use
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019383976B2 (en)	2018-11-19	2025-07-03	Bt Bidco, Inc.	Methods and devices for treating a disease with biotherapeutics
JP7287048B2 (ja)	2019-03-27	2023-06-06	セイコーエプソン株式会社	ロボット
EP3870261B1 (en)	2019-12-13	2024-01-31	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6602684B1 (en)	1998-04-20	2003-08-05	Glycart Biotechnology Ag	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
SK17282000A3 (sk)	1998-05-15	2002-04-04	Imclone Systems Incorporated	Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora
EP2275540B1 (en)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
BR0213761A (pt)	2001-10-25	2005-04-12	Genentech Inc	Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
NZ568769A (en)	2002-10-17	2010-04-30	Genmab As	Human monoclonal antibodies against CD20
PT1572744E (pt)	2002-12-16	2010-09-07	Genentech Inc	Variantes de imunoglobulina e utilizações destas
EP2248892B1 (en)	2003-01-22	2015-04-22	Roche Glycart AG	Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
KR20060012622A (ko) *	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
AU2004261229A1 (en)	2003-07-29	2005-02-10	Eisai, Inc.	Antibodies and methods for generating genetically altered antibodies with enhanced effector function
EP2502935B1 (en)	2003-08-22	2017-03-29	Biogen MA Inc.	Improved antibodies having altered effector function and methods for making the same
US20050152894A1 (en)	2003-09-05	2005-07-14	Genentech, Inc.	Antibodies with altered effector functions
DE602004026470D1 (de) *	2003-11-05	2010-05-20	Roche Glycart Ag	Fc-rezeptor und effektorfunktion
WO2005103081A2 (en)	2004-04-20	2005-11-03	Genmab A/S	Human monoclonal antibodies against cd20
CA2587766A1 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
WO2006114700A2 (en)	2005-04-26	2006-11-02	Bioren, Inc.	Method of producing human igg antibodies with enhanced effector functions
EP1874816A4 (en)	2005-04-26	2010-08-25	Medimmune Inc	MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
RU2547931C2 (ru)	2005-08-26	2015-04-10	Роше Гликарт Аг	Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
ES2642787T3 (es) *	2005-10-21	2017-11-20	Lfb Usa, Inc.	Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2234641B1 (en) *	2008-01-03	2015-08-19	Genmab A/S	Monoclonal antibodies against cd32b
KR20110111303A (ko) *	2009-01-16	2011-10-10	글락소스미스클라인 엘엘씨	벤다무스틴 및 항-ｃｄ２０ 항체의 조합을 이용한 암의 치료
EP2419470B1 (en) *	2009-04-15	2016-03-30	Invista Technologies S.à.r.l.	Improving miscibility of otherwise immiscible compounds

2010
- 2010-08-11 TW TW099126813A patent/TWI409079B/zh active
- 2010-08-12 CN CN201710422477.2A patent/CN107261138A/zh active Pending
- 2010-08-12 PT PT107471682T patent/PT2464382T/pt unknown
- 2010-08-12 PL PL10747168T patent/PL2464382T3/pl unknown
- 2010-08-12 CA CA2769674A patent/CA2769674C/en active Active
- 2010-08-12 AR ARP100102968A patent/AR077866A1/es unknown
- 2010-08-12 MX MX2014015198A patent/MX355849B/es unknown
- 2010-08-12 DK DK10747168.2T patent/DK2464382T3/en active
- 2010-08-12 ES ES10747168.2T patent/ES2630158T3/es active Active
- 2010-08-12 SM SM20170329T patent/SMT201700329T1/it unknown
- 2010-08-12 NZ NZ597666A patent/NZ597666A/xx unknown
- 2010-08-12 WO PCT/EP2010/004939 patent/WO2011018224A1/en active Application Filing
- 2010-08-12 SG SG2012008843A patent/SG178324A1/en unknown
- 2010-08-12 JP JP2012524146A patent/JP5646626B2/ja active Active
- 2010-08-12 SI SI201031491T patent/SI2464382T1/sl unknown
- 2010-08-12 HU HUE10747168A patent/HUE033531T2/hu unknown
- 2010-08-12 KR KR1020127006528A patent/KR101425736B1/ko active Active
- 2010-08-12 HR HRP20170972TT patent/HRP20170972T1/hr unknown
- 2010-08-12 MY MYPI2012000606A patent/MY163003A/en unknown
- 2010-08-12 MA MA34585A patent/MA33469B1/fr unknown
- 2010-08-12 CN CN201080035971XA patent/CN102596245A/zh active Pending
- 2010-08-12 LT LTEP10747168.2T patent/LT2464382T/lt unknown
- 2010-08-12 EP EP10747168.2A patent/EP2464382B1/en active Active
- 2010-08-12 MX MX2012001782A patent/MX2012001782A/es active IP Right Grant
- 2010-08-12 AU AU2010281866A patent/AU2010281866B2/en active Active
- 2010-08-12 RS RS20170647A patent/RS56146B1/sr unknown
- 2010-08-13 US US12/855,827 patent/US20110165151A1/en not_active Abandoned
- 2010-12-08 UA UAA201202678A patent/UA110096C2/ru unknown
2012
- 2012-01-19 CR CR20120036A patent/CR20120036A/es unknown
- 2012-01-26 IL IL217753A patent/IL217753A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00830A patent/ZA201200830B/en unknown
- 2012-02-08 US US13/368,465 patent/US20120315268A1/en not_active Abandoned
- 2012-02-14 CL CL2012000391A patent/CL2012000391A1/es unknown
2013
- 2013-01-18 HK HK18104879.8A patent/HK1245145A1/zh unknown
- 2013-03-06 US US13/787,532 patent/US20140044705A1/en not_active Abandoned
2014
- 2014-05-08 US US14/273,148 patent/US20160166688A9/en not_active Abandoned
- 2014-11-04 JP JP2014224221A patent/JP5963013B2/ja active Active
2016
- 2016-06-15 JP JP2016118739A patent/JP2016222673A/ja active Pending
2017
- 2017-07-03 CY CY20171100706T patent/CY1119251T1/el unknown
- 2017-10-26 LU LU00045C patent/LUC00045I2/fr unknown
- 2017-10-26 NO NO2017054C patent/NO2017054I1/no unknown
- 2017-10-26 CY CY2017034C patent/CY2017034I1/el unknown
- 2017-10-27 HU HUS1700041C patent/HUS000498I2/hu unknown
- 2017-10-31 LT LTPA2017035C patent/LTPA2017035I1/lt unknown

Also Published As

Publication number	Publication date
TW201110980A (en)	2011-04-01
LUC00045I1 (lt)	2017-11-03
JP5963013B2 (ja)	2016-08-03
SI2464382T1 (sl)	2017-08-31
EP2464382A1 (en)	2012-06-20
NO2017054I1 (no)	2017-10-26
LUC00045I2 (lt)	2018-02-26
HUS1700041I1 (hu)	2017-11-28
BR112012002855A2 (pt)	2016-11-01
NZ597666A (en)	2013-10-25
CR20120036A (es)	2012-04-18
RU2012109445A (ru)	2013-09-27
CY2017034I2 (el)	2018-02-14
AR077866A1 (es)	2011-09-28
TWI409079B (zh)	2013-09-21
JP2016222673A (ja)	2016-12-28
US20150093376A1 (en)	2015-04-02
JP5646626B2 (ja)	2014-12-24
CL2012000391A1 (es)	2012-08-24
HUE033531T2 (hu)	2021-12-28
HK1245145A1 (zh)	2018-08-24
SG178324A1 (en)	2012-03-29
MX355849B (es)	2018-05-02
LT2464382T (lt)	2017-07-25
ES2630158T3 (es)	2017-08-18
AU2010281866A1 (en)	2012-02-02
PL2464382T3 (pl)	2017-09-29
CY1119251T1 (el)	2018-02-14
JP2013501740A (ja)	2013-01-17
MX2012001782A (es)	2012-04-19
MY163003A (en)	2017-07-31
JP2015071611A (ja)	2015-04-16
US20110165151A1 (en)	2011-07-07
US20140044705A1 (en)	2014-02-13
US20160166688A9 (en)	2016-06-16
RS56146B1 (sr)	2017-11-30
ZA201200830B (en)	2012-10-31
HRP20170972T1 (hr)	2017-09-22
PT2464382T (pt)	2017-06-30
CN102596245A (zh)	2012-07-18
IL217753A0 (en)	2012-03-29
HUS000498I2 (hu)	2021-03-29
CA2769674A1 (en)	2011-02-17
MA33469B1 (fr)	2012-07-03
AU2010281866B2 (en)	2016-05-12
EP2464382B1 (en)	2017-05-03
DK2464382T3 (en)	2017-07-17
CY2017034I1 (el)	2018-02-14
KR101425736B1 (ko)	2014-08-01
UA110096C2 (uk)	2015-11-25
KR20120054068A (ko)	2012-05-29
CN107261138A (zh)	2017-10-20
CA2769674C (en)	2018-01-23
WO2011018224A1 (en)	2011-02-17
IL217753A (en)	2016-10-31
US20120315268A1 (en)	2012-12-13
SMT201700329T1 (it)	2017-09-07

Publication	Publication Date	Title
LTPA2017035I1 (lt)	2017-11-27	Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu
NO2024044I1 (no)	2024-10-08	Insulin icodec
EP2799452A4 (en)	2015-07-15	ANTI-TROP-2 HUMAN ANTIBODY HAVING IN VIVO ANTI-TUMOR ACTIVITY
BRPI0907231A2 (pt)	2019-09-24	pirrolpirimidinas e pirrolpiridinas
HRP20160737T1 (hr)	2016-07-15	Anti-her3-protutijela i njihove uporabe
PL2544682T3 (pl)	2016-08-31	Fitokannabinoidy w leczeniu glejaka
BR112013008905A2 (pt)	2017-07-11	mecanismo de dosagem e método de dosagem
DE112010001215A5 (de)	2012-07-05	Gurtaufrollersystem mit einsteuerglied
BR112014007243A2 (pt)	2017-04-11	composição, componentes e dispositivo de iluminação
HRP20160577T1 (hr)	2016-07-29	Liječenje osteoartritisa
FI20095020L (fi)	2010-07-13	Menetelmä aukirullaimen yhteydessä
ES1071902Y (es)	2010-07-22	Mecanismo de termosoldadura y precorte
FI20095999A0 (fi)	2009-09-30	Menetelmä pumppukäytön yhteydessä
UA18855S (uk)	2009-05-12	Гіпертермотерапевтичне крісло
DK2310037T3 (da)	2014-10-27	Conglutin-gamma as-medikament og -kosttilskudpatentkrav
DK2306097T3 (da)	2019-10-21	Ventilenhed med flere funktioner
ES1070576Y (es)	2010-01-04	Bionda perfeccionada
PL389509A1 (pl)	2011-05-23	Bioanoda
FI8371U1 (fi)	2009-08-04	Järjestely taajuudenmuuttajassa
TH105708B (th)	2011-01-26	ขวดพร้อมปั๊ม
UY3886Q (es)	2010-03-26	Configuración aplicada en dispensador
UY3960Q (es)	2011-07-29	Configuración aplicada en licuadora
FI20096360A0 (fi)	2009-12-18	Bioliima ja puulevy
TH100148B (th)	2010-02-25	ที่วางแขน
UY4071Q (es)	2011-12-30	Configuración aplicada en triciclo